



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Pre Amoldt
BA
MLW

Applicant : Ernest G. Hope
Serial No. : 09/722,096
Filed : November 22, 2000
Title : ANTI-ANGIOGENIC CELLULAR AGENT FOR CANCER THERAPY

Art Unit : 1623
Examiner :

Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

RECEIVED
JAN 22 2002
TECH CENTER 1600/2900

Please preliminarily amend the application as follows:

In the specification:

Replace the paragraph beginning at page 9, line 8, with the following rewritten paragraph:

A

-- Figures 7A and 7B depict Brefeldin A induced protection of EC from CIK mediated lysis. --

Replace the paragraph beginning at page 31, line 2, with the following rewritten paragraph:

A

--Figures 7A and 7B illustrate the results of an experiment demonstrating that brefeldin A (BFA; a compound which blocks transport of proteins from the golgi to the ER) protects EC from non-MHC I restricted killing. CIK targets were treated with BFA and/or tunicamycin (TM). Pre-treatment with BFA did not reduce killing of tumor or lymphoblastoid targets. However, it did suppress CIK mediated lysis of EC in a ⁵¹Cr release assay (20:1 E:T ratio) with complete protection

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

October 19, 2001
Date of Deposit

Carrie A. Amonte
Signature

Carrie A. Amonte
Typed or Printed Name of Person Signing Certificate

BEST AVAILABLE COPY